NewGenIvf Group Limited (NIVF) AI Stock Analysis

NewGenIVF Group Ltd. is a provider of assisted reproductive services focused on fertility treatments. Headquartered in Bangkok, Thailand, the company offers in-vitro fertilization (IVF) treatments, including traditional IVF methods, egg donation programs, and surrogacy options. It also delivers ancillary care services to support patients throughout the treatment process. Founded to expand access to advanced fertility care, NewGenIVF Group Ltd. combines reproductive technologies with patient-centered solutions to serve individuals and couples seeking family-building options worldwide.

Revenue increased from $4.1M in FY2021 to a peak of $5.9M in FY2022 before dropping to $4.7M in FY2025, reflecting a 4-year compound annual growth rate of 3.5%. Operating margins deteriorated from 4.8% in FY2021 to -226.9% in FY2025. Despite operating losses, net income reached $9.9M in FY2025, yielding a net margin of 209.0%. For the trailing twelve months ended December 31, 2025, revenue stood at $4.6M, operating margin was -184.3%, and diluted earnings per share was -$4258.09. Quarterly revenue fell 4.7% year-over-year in the period ended December 31, 2025.

As of December 31, 2025, NewGenIvf held $758,621 in cash and short-term investments alongside total debt of $4.9M, resulting in net debt of $4.1M. Total assets were $32.7M and shareholders' equity was $26.6M, yielding a debt-to-equity ratio of 0.18 and a current ratio of 3.12. In FY2025, operating cash flow was -$10.9M and capital expenditures were $5.7M, leading to free cash flow of -$16.7M.

At $0.28 per share, NewGenIvf trades at an enterprise value of $5.6M and an EV-to-revenue multiple of 1.2x. Its price-to-sales ratio is 0.4x, below the 4.1x median of its US-listed Healthcare peers. Its EV-to-EBITDA ratio is 0.5x, compared to the peer median of 12.0x. Over the past year, the stock declined 100.0%, lagging the S&P 500 (SPY) return of 16.8%.

Wall Street coverage includes a mean price target of $508.32, which is 182093.6% above the last close of $0.28. For the fiscal year ending December 31, 2026, consensus estimates project revenue of $65.1M and earnings per share of $170.64. For the next fiscal year, 1 analyst projects revenue of $180.4M, representing revenue growth of 177.1%, and earnings per share of $336.24.

This page is an AI-written research summary of NewGenIvf Group Limited (NIVF). The text was generated on October 30, 2026 from Quotelinks data as of October 16, 2026 (company profile, annual results, latest balance sheet, valuation, price performance and analyst estimates). An automatic check rejects any draft that contains a figure not found in that data. It is not investment advice; verify figures on the linked tabs before making decisions.

Related: NIVF income statement, NIVF balance sheet, NIVF key metrics, NIVF analyst forecast, NIVF chart. See the NIVF stock overview for the latest quote and news.